PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 153 products for "PD-1/PD-L1".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.14 kDaSintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purity:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Color and Shape:LiquidMolecular weight:143.78 kDaZimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purity:95%Color and Shape:Transparent LiquidMolecular weight:146.54 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purity:95.07% - 99.29%Color and Shape:White SolidMolecular weight:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purity:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:146.03 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11Ref: TM-T10565
1mg52.00€5mg120.00€1mL*10mM (DMSO)169.00€10mg187.00€25mg380.00€50mg612.00€100mg973.00€200mg1,305.00€Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.72 kDaDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:144.18 kDaTislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purity:95.07%Color and Shape:Transparent LiquidMolecular weight:145 kDaEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.21 kDaSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:Transparent LiquidMolecular weight:145.74 kDaPD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formula:C22H22N2O3Color and Shape:SolidMolecular weight:362.42BMSpep-57
CAS:BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formula:C89H126N24O19SColor and Shape:SolidMolecular weight:1868.2Human PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurity:98%Color and Shape:SolidGarivulimab
CAS:Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Purity:95%Color and Shape:Transparent LiquidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44Ref: TM-T9651
10mgTo inquire25mgTo inquire50mgTo inquire100mgTo inquire500mgTo inquire1mg57.00€2mg85.00€5mg127.00€1mL*10mM (DMSO)140.00€Human PD-L1 inhibitor II
CAS:Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formula:C103H151N25O30Color and Shape:SolidMolecular weight:2219.486TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69Anti-Mouse PD-L1 Antibody (10F.9G2)
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.Purity:98.92% - >95.0% (SDS-PAGE); 99.6% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:150 kDa
